Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2021
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Favorite
0
Like
Facebook
Tweet this
Print
Nicholas Murgolo, PhD
Merck & Co., Inc.
Disclosure:
Merck & Co., Inc.
(Employee, Shareholder)
Poster(s):
511 - Treatment with molnupiravir in the MOVe-In and MOVe-Out clinical trials results in an increase in transition mutations across the SARS-CoV-2 genome
543 - Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies
